

## Accepted Manuscript

Title: A scoping review of trials of interventions led or delivered by cancer nurses

Authors: Andreas Charalambous, Mary Wells, Pauline Campbell, Claire Torrens, Ulrika Östlund, Wendy Oldenmenger, Elisabeth Patiraki, Lena Sharp, Iveta Nohavova, Nuria Domenech-Climent, Manuela Eicher, Carole Farrell, Maria Larsson, Cecilia Olsson, Mhairi Simpson, Theresa Wiseman, Daniel Kelly



PII: S0020-7489(18)30133-0  
DOI: <https://doi.org/10.1016/j.ijnurstu.2018.05.014>  
Reference: NS 3158

To appear in:

Received date: 28-12-2017  
Revised date: 18-5-2018  
Accepted date: 22-5-2018

Please cite this article as: Charalambous A, Wells M, Campbell P, Torrens C, Östlund U, Oldenmenger W, Patiraki E, Sharp L, Nohavova I, Domenech-Climent N, Eicher M, Farrell C, Larsson M, Olsson C, Simpson M, Wiseman T, Kelly D, A scoping review of trials of interventions led or delivered by cancer nurses, *International Journal of Nursing Studies* (2018), <https://doi.org/10.1016/j.ijnurstu.2018.05.014>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**A scoping review of trials of interventions led or delivered by cancer nurses**

Andreas CHARALAMBOUS RN, PhD, Assist Prof, Department of Nursing Studies, Cyprus, University of Technology, Cyprus and DOCENT, Department of Nursing Studies, University of Turku, Finland. Email: [andreas.charalambous@cut.ac.cy](mailto:andreas.charalambous@cut.ac.cy)

Mary WELLS RN, PhD Lead Nurse for Research, Imperial College Healthcare NHS Trust, London, UK Email: [mary.wells5@nhs.net](mailto:mary.wells5@nhs.net)

Pauline CAMPBELL PhD, Research Fellow, Nursing, Midwifery and Allied Health Professions Research Unit (NMAHP RU), Glasgow Caledonian University. Email: [pauline.campbell@gcu.ac.uk](mailto:pauline.campbell@gcu.ac.uk)

Claire TORRENS MSc, Research Fellow, Nursing, Midwifery and Allied Health Professions Research Unit (NMAHP RU), Glasgow Caledonian University. Email: [Claire.Torrens@gcu.ac.uk](mailto:Claire.Torrens@gcu.ac.uk)

Ulrika ÖSTLUND RN, PhD, Research Supervisor, Uppsala University/Region Gävleborg, Centre for Research & Development. Email: [ulrika.ostlund@lnu.se](mailto:ulrika.ostlund@lnu.se)

Wendy OLDENMENGER RN, PhD, Coordinator Oncology Nursing Research, Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Email: [w.h.oldenmenger@erasmusmc.nl](mailto:w.h.oldenmenger@erasmusmc.nl)

Elisabeth PATIRAKI RN, PhD, Professor, Nursing Faculty, School of Health Sciences, National and Kapodistrian University of Athens, Greece. Email: [epatiraki@nurs.uoa.gr](mailto:epatiraki@nurs.uoa.gr)

Lena SHARP RN, PhD, Head of Cancer Care Improvement, Regional Cancer Centre, Stockholm-Gotland, Stockholm, Sweden and Karolinska Institute, Department of Learning Informatics, Management and Ethics, Stockholm, Sweden. Email: [lena.sharp@sll.se](mailto:lena.sharp@sll.se)

Iveta NOHAVOVA RN, MS, PhD Student, Institute of Hygiene and Epidemiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. Email: [nohiveta@gmail.com](mailto:nohiveta@gmail.com)

Nuria DOMENECH-CLIMENT RN, PhD, Oncology Nurse, Sociologist and Associate Professor, Alicante University, Spain. Email: [nuria.domenech@ua.es](mailto:nuria.domenech@ua.es)

Manuela EICHER RN, PhD, Associate Professor, Institute for Higher Education and Research in Healthcare and Nurse Research Consultant Department of Oncology, Lausanne University Hospital and University of Lausanne, Switzerland. Email: [manuela.eicher@chuv.ch](mailto:manuela.eicher@chuv.ch)

Carole Farrell RN, PhD Teaching Fellow/Honorary Lecturer, Division of Nursing, Midwifery & Social Work, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, UK [carole.farrell@manchester.ac.uk](mailto:carole.farrell@manchester.ac.uk)

Maria Larsson RN, PhD, Professor, Faculty of Health, Science and Technology, Department of Health Sciences, Karlstad University, Sweden [maria.larsson@kau.se](mailto:maria.larsson@kau.se)

Cecilia Olsson RN, PhD, Senior Lecturer, Faculty of Health Science and Technology, Department of Health Sciences, Karlstad University, Sweden [cecilia.olsson@kau.se](mailto:cecilia.olsson@kau.se)

Mhairi Simpson Clin Doc, RN, Nurse Consultant Cancer Care, NHS Lanarkshire, Scotland [Mhairi.Simpson@lanarkshire.scot.nhs.uk](mailto:Mhairi.Simpson@lanarkshire.scot.nhs.uk)

Theresa WISEMAN RN, PhD, Clinical Chair of Applied Health in Cancer Care, Strategic Lead for Health Service Research, The Royal Marsden, NHS Foundation Trust, University of Southampton. Email: [theresa.wiseman@rmh.nhs.uk](mailto:theresa.wiseman@rmh.nhs.uk)

Daniel KELLY RN, PhD\*, Royal College of Nursing Chair of Nursing Research & Director of Research and Innovation, Cardiff University, Wales. Email: [KellyDM@cardiff.ac.uk](mailto:KellyDM@cardiff.ac.uk)

**\* Corresponding author**

**Abstract**

**Background:** Advances in research and technology coupled with an increased cancer incidence and prevalence has resulted in significant expansion of cancer nurse role, in order to meet the growing demands and expectations of people affected by cancer (PABC). Cancer nurses are also tasked with delivering an increasing number of complex interventions as a result of on-going clinical trials in cancer research. However much of this innovation is undocumented, and we have little insight about the nature of novel interventions currently being designed or delivered by cancer nurses.

**Objectives:** To identify and synthesise the available evidence from clinical trials on interventions delivered or facilitated by cancer nurses.

**Data sources and review methods:** A systematic review of randomised controlled trials (RCT), quasi-RCTs and controlled before and after studies (CBA) of cancer nursing interventions aimed at improving the experience and outcomes of PABC. Ten electronic databases (CENTRAL, MEDLINE, AMED, CINAHL, EMBASE, Epistemonikos, CDSR, DARE, HTA, WHO ICTRP) were searched between 01 January 2000 and 31 May 2016. No language restrictions were applied. Bibliographies of selected studies and relevant Cochrane reviews were also hand-searched. Interventions delivered by cancer nurses were classified according to the OMAHA System. Heat maps were used to highlight the volume of evidence available for different cancer groups, intervention types and stage of cancer care continuum.

**Results:** The search identified 22450 records; we screened 16169 abstracts and considered 925 full papers, of which 214 studies (247550 participants) were included in the evidence synthesis. The majority of studies were conducted in Europe (n=79) and USA (n=74). Interventions were delivered across the cancer continuum from prevention and risk reduction to survivorship, with the majority of interventions delivered during the treatment phase (n=137). Most studies (131/214) had a teaching, guidance or counselling component. Cancer nurse interventions were targeted at primarily breast, prostate or multiple cancers. No studies were conducted in brain, sarcoma or other rare cancer types.

The majority of the studies (n=153) were nurse-led and delivered by specialist cancer nurses (n=74) or advanced cancer nurses (n=29), although the quality of reporting was poor.

**Conclusions:** To the best of our knowledge, this is the first review to synthesise evidence from intervention studies across the entire cancer spectrum. As such, this work provides new insights into the nature of the contribution that cancer nurses have made to evidence-based innovations, as well as highlighting areas in which cancer nursing trials can be developed in the future.

Keywords: cancer care; clinical trials; interventions; nursing

ACCEPTED MANUSCRIPT

## **Contribution of the Paper**

### **What is already known about the topic?**

- Cancer nurses play a central role in the care of patients with cancer and are the largest single profession working in this field.
- Cancer nurses have employed a range of research approaches to support innovation, including clinical trials.
- Trials by nurses have contributed to the evidence base for clinical innovations.
- The complexity of cancer care, and the demand for evidence-based innovations, will increase with rising demand.

### **What this paper adds**

- A clear summary of the current trial evidence relating to cancer nursing interventions, using the OMAHA classification
- Evidence that cancer nursing interventions may be delivered at all stages of the cancer care continuum, but that the majority to date have focused on adults in the treatment stage
- The majority of cancer nurse-led interventions are delivered by specialist and / or advanced cancer nurses, but details of interventionists are poorly described in trials
- Cancer nurse-led trial evidence focusses primarily on mixed cancer groups, or on people with breast or prostate cancer, highlighting gaps for future research.

## INTRODUCTION

Cancer nurses represent the largest group of healthcare professionals providing care to people living with and beyond, or at risk of cancer, across all age groups and settings (WHO, 2012). Cancer nurses are also central to all stages of care, including screening, early detection, assessment, education, administration of treatments, supportive care including identification/management of symptoms, side-effects and complications; coordination of care, palliative and end of life care (Ferrell et al., 2010, Fox et al., 2017, Klemp, 2015). Alongside developments in care and treatment, cancer nurses have developed a range of new roles and responsibilities to support people living with, beyond, or at risk of cancer.

Various drivers have influenced the development of new and more autonomous nursing roles and functions for cancer nurses. First, contemporary cancer treatment is becoming increasingly complex and individualized, characterised by constant advances in therapy such as treatments relying on molecularly targeted agents and immunotherapies that require the adoption of a more personalised approach to care (Clauser et al., 2011). Second, the continuing shift from hospitalised cancer care to outpatient-based care has promoted the development of more independent roles for nurses, including symptom management and follow-up interventions (Bergin et al., 2016, Latter et al., 2017). Third, the specialty of cancer nursing has expanded rapidly, driven in part by current fiscal challenges in the global economy and a range of workforce pressures within the field of oncology, but also in response to the changing demographics and expectations of people living with, beyond, or at risk of cancer. These economic and political drivers have resulted in greater substitution of roles and task-shifting from physicians to specialized nurses with advanced and extended roles, e.g. nurse practitioners.

Innovation and developments in cancer nursing should be underpinned by a robust evidence-base. Furthermore, cancer nursing interventions are becoming increasingly complex, and the evaluation of their effectiveness necessitates significant scientific investment. It is therefore important that we understand both the contribution cancer nurses make to patient care and the current state of trials-based evidence, in order to inform the development and evaluation of innovative and sustainable healthcare services and interventions. In 2015, the European CanCer

Organisation (ECCO) supported an initiative to increase the recognition of the contributions made by cancer nursing, resulting in the Recognising European Cancer Nursing (RECaN) project. The first phase of this ambitious project was to conduct a systematic scoping review to document the interventions delivered by cancer nurses; to identify the way that cancer nurses have contributed to such interventions; and then to determine their effectiveness. Here, we present the findings of the scoping review that was the first step in this process.

## **METHODS**

We conducted a systematic scoping review of randomised controlled trials (RCT), quasi-RCTs and controlled before and after studies (CBA) of cancer nursing interventions aimed at improving the experience and outcomes of people living with, beyond, or at risk of cancer. Our review was conducted to agreed methodological and reporting standards (Higgins and Green, 2011, Liberati et al., 2009). The review analysis and inclusion criteria were specified in advance and documented in a protocol (Campbell et al., 2017). The review protocol is registered in PROSPERO (ID= CRD42016048760).

### **Identification of studies for inclusion**

Multiple electronic databases (Medline, AMED, Epistemonikos, CINAHL, Embase, Cochrane Central Register of Controlled, DARE, HTA, CDSR), clinical trial registries (WHO ICTRP) from 01 January 2000 to 30 May 2016 were searched systematically. No language restrictions were employed. Bibliographies of selected studies and relevant Cochrane reviews were also hand-searched in order to identify any further relevant studies not detected by the electronic search.

A comprehensive search strategy was developed, combining key terms using a series of free text terms and MESH terms for: profession and/role (e.g. nurse; nurse practitioner; cancer nurse; oncology nurse) and Cancer (e.g. neoplasm; tumour). An example search strategy is provided in Supplementary Table 1.

### ***Eligibility criteria***

We included RCTs, quasi-RCTs and CBAs of cancer nursing interventions delivered to participants screened for, diagnosed with or treated for cancer, irrespective of their age.



Cancer nursing interventions were defined, following a pragmatic approach, as any intervention(s) delivered by a nurse to a person with cancer, using the Canadian Association of Nurses in Oncology (CANO) definition for generalist, specialist and advanced oncology nurse (CANO, 2016). Such interventions could be psychological, educational, clinical or behavioural, provided they were aimed at people living with, beyond or at risk of cancer. We excluded all studies, where interventions were aimed primarily at nurses e.g. through education, without any associated patient-reported outcome data.

All study designs or CBA studies in which historical data was used as a comparison, but was collected for a different purpose at the time were excluded. We also excluded studies on any pharmacological or surgical only intervention, or any intervention delivered by healthcare professionals who are not professionally qualified nurses (e.g. support staff).

### **Study selection**

One reviewer (PC) conducted the searching and initial screening. Two reviewers (PC, CT) independently applied the predefined selection criteria to the remaining records. Consensus meetings with a third reviewer (MW) were organised to discuss any disagreement regarding selection. Full publications were retrieved for studies that met the selection criteria and for those for which this was unclear.

### **Data collection and management**

One review author (CT) systematically extracted key information relating to the intervention in accordance with the Template for Intervention Description and Replication (TIDieR) guidelines (i.e. procedures, intervention provider and training, mode and location of intervention delivery and the regime) (Hoffmann et al., 2014). A second review author (PC) checked these data and any disagreements that arose were resolved by discussion between the review authors. Where insufficient information was available, requests were sent to the original authors.

### **Mapping and coding categories**

Following data extraction, all included studies were coded by cancer type, stage of cancer trajectory, care setting, level of nurse involved and nature of intervention.

***Cancer trajectory, type and care setting***

Included studies were coded according to the stage of the cancer care continuum in which the intervention was delivered (i.e. prevention and risk reduction, screening, diagnosis, treatment, survivorship or end of life), using the cancer care continuum framework.

---

Insert figure 1 about here

---

Reviewers also independently coded the type of cancer using the National Cancer Research Institute's Clinical Studies Groups as a guide <http://csg.ncri.org.uk/groups/clinical-studies-groups/>. This included 15 possible codes: advanced cancer, bladder and renal (including penile), brain (includes CNS), breast, colorectal/anus, gynaecological, haematological oncology (leukaemias and myeloma), head and neck, lung, lymphoma, prostate, sarcoma, skin cancer, testis, upper gastro-intestinal (includes neuroendocrine). Where more than one type of cancer was described, reviewers classified this as 'multiple'. Studies that screened participants for cancer were coded separately.

Studies were also coded according to the setting of care e.g. hospital inpatient or outpatient setting, home or primary care setting.

***Level of Nurse***

Three reviewers with content expertise (UO, EP, TW) coded the level of nurse responsible for delivering the intervention using the CANO classifications of generalist, specialist and advanced nurse (CANO, 2016).

***Classification of interventions***

A series of team discussions were held to reach consensus on methods for grouping interventions from the included studies into relevant categories. Using an iterative process, involving discussion between pairs or groups of review authors with expertise relating to cancer nursing (MW, UO, EP, ME, LS, ML, CO, MS, CF, WO), an agreement was reached to use the categories proposed by the OMAHA nursing intervention classification as these were deemed more relevant to the aim of this review (OMAHA, 2016, Topaz et al., 2014).

This classification system includes four core categories:

1. Case Management
2. Surveillance
3. Teaching, Guidance, and Counselling
4. Treatments and Procedures

Two independent reviewer pairs were asked to consider both the *nature* of the role taken by the nurse in the intervention as well as what the intervention actually was. Table 1 summarises the different OMAHA categories and approaches agreed *a priori* by the reviewers when coding the interventions. Many interventions were complex and included a number of different components. In these cases, they were classified according to the OMAHA category which best encompassed the nature of the intervention. Any disagreements between reviewer pairs were resolved by a third reviewer. The methodological application of the OMAHA categories, tasks and components for the classification of cancer nursing will be published in more detail elsewhere.

### **Data synthesis**

Data from all included studies were synthesised within evidence tables and narrative, categorised according to OMAHA categories. Heat maps were generated in Excel (Microsoft). Conditional formatting was employed and those values with the highest frequency were assigned a red colour, middle values a yellow colour and lowest values a green colour.

## **RESULTS**

### **Results of the search**

Our searching identified 22450; screened 16169 abstracts and considered 925 full papers. Results of the search are displayed in Figure 1. Of the 925 potentially relevant studies, 518 studies were excluded. Reasons for exclusion were primarily due to inadequate description of the interventionist, or the intervention did not include a cancer nurse or the study design failed to meet selection criteria. We identified 83 studies as on-going (i.e. published protocols or on-going trials) and 18 studies as awaiting assessment (i.e. studies requiring translation or missing information sought but not available or full text papers were unavailable), leaving 316 reports of

214 unique studies that were eligible for inclusion within the narrative synthesis (Supplementary Tables 2 – 5) (Figure 1).

### **Description of included studies**

We included a total of 214 studies (247550 participants) in this review. Geographical locations of the included studies are shown in Supplementary Tables 2 –5. The majority of studies were conducted in Europe (n=79) or USA (n=74). Of the 214 included studies, 153 were nurse-led and 61 studies were nurse-facilitated (meaning that they were delivered by cancer nurses, as part of a wider multidisciplinary team).

The distribution of OMAHA heat map categories across all the included studies for cancer type is shown in Figure 2 and data are presented by trajectory in Figure 3. The greatest number of studies focused on teaching, guidance and counseling interventions in patients with multiple (two or more types) cancers and those with breast and prostate cancer. Studies on rare cancers were scarce.

### **Intervention descriptions**

In the following section, a brief overview of the interventions categorised according to the OMAHA nursing intervention classification is given:

1. Case management (n=38) (Supplementary Table 2)
2. Surveillance (n= 27) (Supplementary Table 3)
3. Teaching, counselling and guidance (n=131) (Supplementary Table 4)
4. Treatment and procedures (n = 18) (Supplementary Table 5)

#### ***Case management***

Thirty-eight studies (57193 participants) were categorised as case management, most commonly employing a parallel RCT design (n=26). The sample size varied across studies from 20 – 49311 participants. Most studies included 101 – 500 participants (n=27). Case management

studies involved adult (or older adult) participants in 37 studies; only one trial included a mixed population of people with cancer and their carers (Supplementary Table 2).

Over half of the studies in this category included participants with a range of different cancer types (classed as 'multiple') (n=20) (Supplementary Table 2, Figure 2). The majority of these studies were focused on the phase of cancer treatment (n=20) and end-of-life (n=12) (Figure 3).

The most common focus of case management interventions was the provision of supportive care or psychosocial and/or psychosexual care. Other common components of these interventions were the management of signs and symptoms, primarily emotional and continuity of care (Supplementary Table 2). Specialist oncology nurses (n=13) or advanced cancer nurses (n=12) delivered the majority of interventions (n=23), however a variety of descriptors were used to document their professional roles, education and training (Supplementary Table 2, Figure 4).

The number of contacts for delivering case management interventions were clearly reported in 23 studies and ranged from 1- 18 contacts (face-to-face and telephone), Supplementary Figure 5a. The length of interventions ranged widely from 1.5 to 260 weeks (Supplementary Figure 5b). The amount of time attributed to case management interventions delivered by cancer nurses ranged from 120 to 1377 minutes per participant (Supplementary Table 2).

### ***Surveillance***

Twenty-seven studies (4892 participants) were included in the surveillance category. All of the participants were adults. Sample size ranged from 43 – 775 participants. Six studies included less than 100 participants with the majority of studies (n=21) including between 101 – 500 participants.

The majority of studies in this category focused on women with breast cancer (n=8). Over half of the interventions in 16/27 studies were delivered in the treatment phase of the cancer trajectory. However, a third of studies classed as surveillance interventions (9/27) took place in the survivorship phase. The descriptions of components involved interventions aimed at assessment, managing signs and symptoms, encouraging self-management and supportive care.

Specialist nurses delivered the majority of surveillance interventions; however once again a variety of descriptors were used to document their professional education and training (Figure 4, Supplementary Table3)

All of the interventions were delivered on a 1-to-1 basis. Most studies included face-to-face and telephone contact; 8 were telephone interventions only (no face-to-face contact) and 4 had additional e-health / computer delivered components. Interventions were mainly delivered in an outpatient or home based environment. The intervention regime varied across studies from 1 to 25 sessions; total amount of time attributed to the interventions ranged from 30 to 675 mins (n=14 studies) and was delivered over 1 week to 260 weeks (Supplementary Figure 5a-b, Supplementary Table 3).

### ***Teaching, guidance and counselling***

The majority of studies were categorised as teaching, guidance and counselling (n=131; 182075 participants). Although most of the studies were conducted with adults, 15/131 had a mixed population, including people with cancer and their partners (n=9/16), or people with cancer and Health Care Personnel (HCP - 6/16); 1/16 included family members, HCP and people with cancer. Five studies in this category included children and young people as participants. The sample size across studies ranged from 18 – 138392 participants, with most studies ranging between 101 – 500 participants (n=62). Studies on screening recruited the highest number of participants. The interventions in this category were delivered to people with multiple types of cancer (n=45) but women with breast cancer (n=34) and men with prostate cancer (n=13) also received teaching, guidance and counselling interventions (Figure 2). Interventions in this category were delivered across the entire cancer care continuum with the majority delivered in the treatment phase of the cancer trajectory (86/131) (Figure 3).

The main components of the interventions delivered in this category comprised of education and provision of psychosocial and psychosexual support or helping people with cancer manage symptoms (e.g. pain management, fatigue). Other interventions focused on exercise, genetics and activities aimed at promoting self-management and self-care (Table 4).

Although cancer nurses delivered the majority of interventions; details reporting their education and training were often vague, describing nurses as “experienced” or “trained”; with details of education unreported in over a third of studies (n=52/131) (Supplementary Table 4).

Where reported most interventions were provided in broadly similar settings to those described in other intervention categories. Most interventions were provided on an individual and face-to-face basis; although a number of trials delivered the intervention in a group setting. Intervention regime varied across studies from 1 to 18 sessions (or contacts); total amount of time attributed to the interventions ranged from 3 to 1260 minutes delivered over 1 week to 104 weeks.

### ***Treatment and procedures***

Eighteen studies (3390 participants) were included in the treatment and procedures OMAHA category. The majority of studies were conducted with adults (n=14); 3 studies included children and young people only. Sample size varied across studies from 7 – 844 participants. The majority of studies (11/18) included less than 100 participants. Five out of the eighteen trials included participants with a range of different cancer types (i.e. interventions were delivered to ‘multiple’ disease groups) (Supplementary Table 5). Interventions in 15/18 studies were delivered in the treatment phase of the cancer trajectory.

The main components of the interventions delivered in this category comprised screening procedures (e.g. endoscopy or colonoscopy), interventions targeting signs and symptoms in people affected by cancer using techniques such as massage, Hickman line insertions or decision algorithms. Other interventions focused on medication administration (Supplementary Table 5) and activities aimed at improving physical care including exercise and lymphatic drainage in women with breast cancer. Specialist cancer nurses delivered the intervention in 4 studies, but the education and training details in the majority of this category (n=10) were unclear (Figure 4).

Most interventions were provided on an individual and face-to-face basis. Where reported, the interventions were provided primarily in the hospital setting and were delivered in single session (n=9) (Table 6). However, the amount of time attributed to the interventions varied widely across studies from a single (brief 15 minute) intervention to more time intensive intervention of 21 sessions delivered over 72 weeks (Supplementary Figure 5a-b).

## DISCUSSION

### Key findings

Our review presents evidence of cancer nurses being actively engaged in a large number of trials, delivering complex, often very diverse, interventions across the entire cancer spectrum. Interventions were often multifaceted, with the majority of interventions targeting people living with cancer during the treatment phase, and delivered in a variety of settings. Interventions included direct care, psychological support, teaching, assessment and monitoring, care management and coordination, and were delivered face-to-face; via telephone and online; to individuals and groups. The interventions varied in duration and intensity with the majority requiring between 1-6 sessions (contacts), delivered over 13 – 26 weeks, and therefore consumed a significant time resource for nurses. In the context of a rapidly developing evidence base, the multidimensional role played by cancer nurses in studies documented in this review, covers all aspects of the ICN definition of nursing (ICN, 2002), providing the first broad picture of cancer nursing interventions delivered within clinical trials.

The majority of interventions in this review were nurse-led, but cancer nurses also clearly facilitated a number of interventions as part of a wider team. With multi-professional teams, consisting of medical, nursing, allied professionals, and diagnostic experts, now firmly established at the heart of cancer care (Taylor et al., 2013), cancer nurses can be seen to have established a core co-ordination role within these teams by acting as the patient's key worker and thereby a consistent point of reference through the care pathway (Lafferty et al., 2011). As the context of healthcare delivery is changing rapidly, with greater outpatient care and more emphasis on self-management for the increasing number of people living with and beyond cancer, the need for innovation in nursing is increasing (Macmillan Cancer Support, 2014). For some years, nurses have taken on novel and more autonomous roles (Cancer Services Collaborative Improvement Partnership, 2005), a situation set against a landscape of an increasingly pressured financial climate, and in the context of a global shortage of nurses. (Beans, 2016, Lancet Oncology, 2015). Understanding the nature, breadth and effectiveness of such roles, and the innovations that they have championed as described here, may help support the case for investment in what is an increasingly scarce nursing resource. Healthcare organizations are now having to deal with competing and complex demands, and the need for



effective cancer care, alongside other chronic diseases, exists in a context of rising expectations to deliver more with the same, or even fewer resources. This review indicates where research attention has been paid to innovations in nursing in cancer care, and where gaps still exist.

The majority of trials in this review recruited adults; we identified few studies involving children and adolescents or young adults. Furthermore, most studies recruited patients with two or more types of cancer; fewer studies focused solely on people diagnosed with a single cancer type (i.e. breast, prostate and colorectal/anus cancer). The review identified no nurse-led or nurse-facilitated studies in people diagnosed with brain, bladder and renal, skin cancer, sarcomas and testis cancers. The lack of studies in these areas could be explained by the type of study design criteria in our review, and it is likely that other study designs (e.g. qualitative studies) with fewer ethical barriers may have explored the experiences of these groups and people diagnosed with other 'rarer' cancers in more detail. Importantly, our review highlights a gap in the current evidence base, suggesting a need for more evidence in these disease groups, and high quality cancer nursing trials across all groups.

Cancer nursing interventions were delivered across the continuum from prevention and risk reduction to survivorship. Most interventions were delivered during the treatment and survivorship phases. Fewer interventions were delivered during the diagnostic phase. This was a surprising finding as an increasing body of literature strongly supports the presence of a nurse during the diagnosis of cancer (Gilbert et al., 2011, Mertz et al., 2017). Perhaps less surprisingly, the majority of cancer nursing interventions in this review were classified as teaching, guidance and counselling interventions, with fewer interventions focused on case management, surveillance or treatment. Cancer nurses have traditionally had a significant role to play in supporting patients through information provision, education and psychological support, but are also increasingly engaged in delivering complex treatments, undertaking diagnostic procedures, leading follow-up and survivorship care and managing treatment pathways. Robust evidence to underpin these interventions is urgently needed.

As most trial interventions were delivered by specialist or advanced cancer nurses this has clear implications for education and workforce planning. This finding supports the benefits gained from providing a robust career structure for cancer nurses, with relevant education, that

promotes research skills underpinned by the necessary mentoring and support. The demands likely to be placed on cancer services in the future suggest that effective and affordable nurse-led interventions are going to be required in greater numbers to meet the needs of different cancer groups (Kelly and Charalambous, 2017, NHS, 2017). Comprehensive education, training and support for cancer nurses is needed in order for them to take on more flexible roles, and to extend their competency, in both practice and research, across the cancer care continuum (EONS, 2018, RCN, 2017).

There are also a number of implications for research and practice. The quality of reporting of trials of cancer nursing interventions could be significantly improved. For example, in this review nurse trialists often failed to report on interventionist details adequately (e.g. qualifications and training) in 40% of the included studies. Journals should encourage trialists to provide full descriptions and profiles of the interventionists as well as the interventions themselves (Wells et al., 2012), using recent reporting guidelines (TiDIER) (Hoffmann et al., 2014). Such detail is essential if we are to capture all interventions delivered by cancer nurses and to understand the full extent (and impact) of cancer nursing involvement in trials, as well as implementing new evidence into practice. Additionally, there is a need for more robust research from countries and healthcare contexts across Europe and further afield. Investment in collaborations to build international studies is a crucial step if we are to build a contextually meaningful and convincing evidence base for interventions that are led or delivered by cancer nurses.

### **Strengths and Limitations**

The study has a number of strengths and limitations. While we are confident we have identified most published trials of relevance to the review it is possible, despite our best efforts, that we may be unaware of additional work. For example, we were unable to include a number of trials because details of the interventionist were not reported, or were reported only poorly.

Although we contacted the original authors where possible, some data pertaining the reviewed studies were unavailable.

The use of the OMAHA classification system (OMAHA, 2016, Topaz et al., 2014), although a

widely employed measure to categorise general nursing interventions, may have oversimplified the scope of some interventions. However, we are unaware of any cancer nursing-specific intervention classification systems. An area that has not received adequate attention in the reviewed studies, nor has been captured in this review, is the question of translational impact by findings being taken up in practice. Whether, and to what extent, these trials have led to the greater implementation of cancer nursing interventions, especially in other practice settings, remains unknown.

Furthermore, the degree to which these findings support the call for upskilling cancer nurses in specific areas of practice has not been established. It is, however, likely that the interventions evaluated in the 214 trials in this review, represent only a fraction of those actually delivered by cancer nurses internationally. We also acknowledge that the scoping review is based on trials published between 2000 and 2016 only, and that historical as well as more recent papers may have added to the body of knowledge presented here.

Previous reviews of cancer nursing interventions have focused solely on one type of intervention, or type of cancer (Campbell et al., 2017). Despite acknowledged limitations, this review provides the first comprehensive picture of the cancer nurse interventions that have been introduced and trialled across clinical settings, at different points of the cancer trajectory, and aimed at diverse cancer populations.

### **Conclusion**

Our review has clearly captured the breadth and scope of cancer nurses in delivering interventions within a trial design. Cancer nurses are performing multiple and increasingly complex roles in a variety of settings across the care continuum. The roles are diverse, requiring considerable expertise in many specialist areas of clinical cancer care, in addition to research skills. This review provides novel insights to enhance our current understanding of cancer nurses' evolving roles as trialists, and identifies the focus, to date, for the delivery of complex interventions by cancer nurses. As such, it forms the basis of an ongoing dialogue that we hope will transform awareness of the extent and level of contribution that cancer nurses are making to improve cancer care. In an era of distributed knowledge and search for cost-effective innovation to meet demand we suggest that the contribution of cancer nursing should be better

recognized. Whilst the review has clear relevance to the European context, having been conducted by members of the European Oncology Nursing Society, we suggest that these findings also have global currency given the rising demand now being placed on cancer services around the world.

ACCEPTED MANUSCRIPT

**Authors' contributions**

All authors have agreed on the final version and meet at least one of the following criteria [recommended by the ICMJE (<http://www.icmje.org/recommendations/>)]:

- substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data;
- drafting the article or revising it critically for important intellectual content.

**Conflict of interest**

No conflict of interest has been declared by the authors.

**Acknowledgements**

This project is jointly funded by the European Oncology Nursing Society (EONS) and the European Cancer Organisation (ECCO).

ACCEPTED MANUSCRIPT


## References

- Beans, B.E., 2016. Experts Foresee a Major Shift From Inpatient to Ambulatory Care. *P T* 41 (4), 231-237.
- Bergin, R.J., Grogan, S.M., Bernshaw, D., Juraskova, I., Penberthy, S., Mileskin, L.R., Krishnasamy, M., Hocking, A.C., Aranda, S.K., Schofield, P.E., 2016. Developing an Evidence-Based, Nurse-Led Psychoeducational Intervention With Peer Support in Gynecologic Oncology. *Cancer Nurs* 39 (2), E19-30.
- Campbell, P., Torrens, C., Kelly, D., Charalambous, A., Domenech-Climent, N., Nohavova, I., Ostlund, U., Patiraki, E., Salisbury, D., Sharp, L., Wiseman, T., Oldenmenger, W., Wells, M., 2017. Recognizing European cancer nursing: Protocol for a systematic review and meta-analysis of the evidence of effectiveness and value of cancer nursing. *J Adv Nurs* 73 (12), 3144-3153.
- Cancer Services Collaborative Improvement Partnership, 2005. Applying high impact changes to cancer care: Excellence in cancer care. Cancer Services Collaborative Improvement Partnership, NHS Modernisation Agency, Leicester, UK.
- CANO, 2016. Canadian Association of Nurses in Oncology (CANO): Roles in oncology nursing.
- Clauser, S.B., Wagner, E.H., Aiello Bowles, E.J., Tuzzio, L., Greene, S.M., 2011. Improving modern cancer care through information technology. *Am J Prev Med* 40 (5 Suppl 2), S198-207.
- EONS, 2018. Cancer nursing education framework. Brussels.
- Ferrell, B., Virani, R., Malloy, P., Kelly, K., 2010. The preparation of oncology nurses in palliative care. *Semin Oncol Nurs* 26 (4), 259-265.
- Fox, P., Darley, A., Furlong, E., Miaskowski, C., Patiraki, E., Armes, J., Ream, E., Papadopoulou, C., McCann, L., Kearney, N., Maguire, R., 2017. The assessment and management of chemotherapy-related toxicities in patients with breast cancer, colorectal cancer, and Hodgkin's and non-Hodgkin's lymphomas: A scoping review. *Eur J Oncol Nurs* 26, 63-82.
- Gilbert, J.E., Green, E., Lankshear, S., Hughes, E., Burkoski, V., Sawka, C., 2011. Nurses as patient navigators in cancer diagnosis: review, consultation and model design. *Eur J Cancer Care (Engl)* 20 (2), 228-236.
- Higgins, J.P.T., Green, S., 2011. *Cochrane Handbook for Systematic Reviews of Interventions* (version 5.1). The Cochrane Collaboration, <http://www.cochrane-handbook.org/>.
- Hoffmann, T.C., Glasziou, P.P., Boutron, I., Milne, R., Perera, R., Moher, D., Altman, D.G., Barbour, V., Macdonald, H., Johnston, M., Lamb, S.E., Dixon-Woods, M., McCulloch, P., Wyatt, J.C., Chan, A.W., Michie, S., 2014. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. *BMJ* 348, g1687.
- ICN, 2002. Definition of Nursing. International Council of Nursing, Canada.
- Kelly, D., Charalambous, A., 2017. Recognising the impact and future potential of cancer nursing: The RECaN project and beyond. *European Journal of Oncology Nursing* 29, A1-2.
- Klemp, J.R., 2015. Breast cancer prevention across the cancer care continuum. *Semin Oncol Nurs* 31 (2), 89-99.
- Lafferty, J., Rankin, F., Duffy, C., Kearney, P., Doherty, E., McMenamin, M., Coates, V., 2011. Continuity of care for women with breast cancer: a survey of the views and experiences of patients, carers and health care professionals. *Eur J Oncol Nurs* 15 (5), 419-427.
- Lancet Oncology, 2015. The importance of nurses in cancer care [Editorial]. *The Lancet. Oncology* 16, 737.
- Latter, S., Hopkinson, J.B., Lowson, E., Hughes, J.A., Hughes, J., Duke, S., Anstey, S., Bennett, M.I., May, C., Smith, P., Richardson, A., 2017. Supporting carers to manage pain medication in cancer patients at the end of life: A feasibility trial. *Palliat Med*, 269216317715197.

- Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gotzsche, P.C., Ioannidis, J.P., Clarke, M., Devereaux, P.J., Kleijnen, J., Moher, D., 2009. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 339, b2700.
- Macmillan Cancer Support, 2014. A competence framework for nurses: Caring for patients living with and beyond cancer. UK.
- Mertz, B.G., Dunn-Henriksen, A.K., Kroman, N., Johansen, C., Andersen, K.G., Andersson, M., Mathiesen, U.B., Vibe-Petersen, J., Dalton, S.O., Envold Bidstrup, P., 2017. The effects of individually tailored nurse navigation for patients with newly diagnosed breast cancer: a randomized pilot study. *Acta Oncol* 56 (12), 1682-1689.
- NHS, 2017. Multi-professional framework for advanced clinical practice in England. NHS, UK.
- OMAHA, 2016. The OMAHA System: Solving the clinical data-information puzzle.
- RCN, 2017. Career and education framework for cancer nursing. Royal College of Nursing, UK.
- Taylor, C., Shewbridge, A., Harris, J., Green, J.S., 2013. Benefits of multidisciplinary teamwork in the management of breast cancer. *Breast Cancer (Dove Med Press)* 5, 79-85.
- Topaz, M., Golfenshtein, N., Bowles, K.H., 2014. The Omaha System: a systematic review of the recent literature. *J Am Med Inform Assoc* 21 (1), 163-170.
- Wells, M., Williams, B., Treweek, S., Coyle, J., Taylor, J., 2012. Intervention description is not enough: evidence from an in-depth multiple case study on the untold role and impact of context in randomised controlled trials of seven complex interventions. *Trials* 13, 95.
- WHO, 2012. Enhancing nursing and midwifery capacity to contribute to the prevention, treatment and management of non-communicable diseases. World Health Organisation, Geneva.



Figure 1. PRISMA Flow Diagram



**Figure 2. The distribution of OMAHA heat map categories across all the included studies (n=214) for cancer type.** Values with the highest frequency were assigned a red colour, middle values a yellow colour and lowest values a green colour.

	Case Management	Surveillance	Teaching, Guidance, and Counselling	Treatments and Procedures	Total
Advanced cancer (not specified)	3	1	3	0	7
Bladder & Renal (includes penile)	0	0	0	0	0
Brain (includes CNS)	0	0	0	0	0
Breast	5	8	34	3	50
Colorectal/anus	2	5	5	3	15
Gynaecological	3	2	1	0	6
Haematological Oncology	0	0	4	2	6
Head & Neck	0	3	2	0	5
Lung	3	2	4	1	10
Lymphoma	0	0	1	1	2
Prostate	0	1	13	1	15
Sarcoma	0	0	0	0	0
Skin Cancer	0	0	0	0	0
Testis	0	0	0	0	0
Upper GI	0	0	1	0	1
Multiple	20	5	45	5	75
S&P	2	0	18	0	20
NR	0	0	0	2	2
<i>Total</i>	38	27	131	18	214

**Figure 3. (A) The distribution of OMAHA heat map categories plotted across all the included studies (n=214) for cancer trajectory. (B) OMAHA heat map categories plotted by participant numbers within each study for each stage of the cancer continuum. Values with the highest frequency were assigned a red colour, middle values a yellow colour and lowest values a green colour.**

(A)	Case Management	Surveillance	Teaching, guidance and counselling	Treatment and procedures	Total
Prevention and Risk reduction	0	0	6	0	6
Screening	2	0	12	3	17
Diagnosis	0	0	1	0	1
Treatment	20	16	86	15	137
End-of-life	12	2	2	0	16
Survivorship	4	9	24	0	37
<i>Total</i>	38	27	131	18	214

(B)	Case Management	Surveillance	Teaching, guidance and counselling	Treatment and procedures	Total
Prevention and Risk reduction	0	0	2873	0	2873
Screening	49458	0	158279	1725	209462
Diagnosis	0	0	97	0	97
Treatment	4706	3044	16405	1665	25820
End-of-life	2422	248	106	0	2776
Survivorship	607	1600	4315	0	6522
<i>Total</i>	57193	4892	182075	3390	247550

**Figure 4.** Bar graph showing the level of nurse interventionist using the CANO 2016 descriptors.

Key: ADV: advanced, CM: case management intervention category; GEN: general nurse, SPEC: specialist nurse; SURV: surveillance intervention category; TGC: teaching, guidance and counselling intervention category; TP: treatment and procedure intervention category; UNC: unclear; >1 type (more than one type of nurse included in the study)




Table 1. Criteria for classification of interventions using the OMAHA core categories

OMAHA category	OMAHA description	Additional descriptors guiding decisions made by the RECaN team
<b>Case Management</b>	Activities such as coordination, advocacy, and referral that facilitate service delivery, improve communication among health and human service providers, promote assertiveness, and guide the individual/family/community toward use of appropriate resources.	Interventions which involved a variety of coordinated activities were classified here, including, for example, most palliative home care interventions. Other nurse-led interventions which involved teaching and support, monitoring symptoms or medications and liaising with other health professionals (i.e. were a combination of all four core categories or described a stepped care approach involving a range of interventions) were coded as case management.
<b>Surveillance</b>	Activities such as detection, measurement, critical analysis, and monitoring intended to identify the individual/family/community's status in relation to a given condition or phenomenon.	Interventions described as nurse-led follow up were usually coded to this category, however, where it was clearly described that the intervention involved complex co-ordination of care and symptom management and a range of different activities we coded this to CASE management. Interventions directed at assessing and/or monitoring symptoms, providing tailored advice for those symptoms, reporting back to oncologists etc were also categorised here.
<b>Teaching, Guidance, and Counselling</b>	Activities designed to provide information and materials, encourage action and responsibility for self-care and coping, and assist the individual/family/community to make decisions and solve problems	Where the intervention was described as an educational or counselling intervention and where teaching, providing information or psychosocial support were the primary focus, and these were provided using a structured protocol and for a specific aspect of care, we used this category. We included CBT interventions and those directed at equipping carers to manage care in this category. Interventions targeted at improving specific symptoms e.g. fatigue, through a mixture of education, teaching exercise and strategies were also included here. However, if the intervention involved education AND symptom assessment, management, coordination of care and other specialists, with a particular nurse-led focus we used the category CASE Management. If the

		intervention was primarily symptom focussed and included changing or administering medication it was classified as TREATMENT. However, if it was primarily symptom focussed and mainly about assessment and tailored advice /intervention for that symptom it was classified as Surveillance.
<b>Treatments and Procedures</b>	Technical activities such as wound care, specimen collection, resistive exercises, and medication prescriptions that are designed to prevent, decrease, or alleviate signs and symptoms of the individual/ family/ community.	Under this category we included interventions where the nurse provided a treatment or was responsible for a specific procedure, including massage, diagnostic procedures such as endoscopy, or for managing medication.

ACCEPTED MANUSCRIPT